BRCA Gene Mutation

Novel Pathway Improves Access to Genetic Testing for Women With Ovarian Cancer

Novel Pathway Improves Access to Genetic Testing for Women With Ovarian Cancer

By

Rapid, robust, and affordable genetic testing for patients with ovarian cancer that allows a much larger portion of patients to benefit from personalized cancer management and their relatives to benefit from preventive strategies can be achieved.

Prophylactic Gynecologic Resections Increase Risk for Aggressive Uterine Cancer in BRCA Gene Mutation Carriers

By

Women who carry the BRCA1 mutation are at increased risk for serous/serous-like endometrial carcinoma after risk-reducing salpingo-oophorectomy. Yet uncertainty exists over the need to perform a full hysterectomy in these women.

<i>BRCA1</i> Mutations May Raise Risk of Serous and Serous-Like Uterine Cancer

BRCA1 Mutations May Raise Risk of Serous and Serous-Like Uterine Cancer

Although overall risk for uterine cancer after risk-reducing salpingo-oophorectomy is not increased, the risk of serous/serous-like endometrial carcinoma is higher for BRCA1+ women.

Cell Changes in Fallopian Tubes of BRCA Mutation Carriers May Lead to Strategies for Preventing Ovarian Cancer

By

Recognition of early changes in the Fallopian tube cells of BRCA gene mutation carriers may be key to new strategies for preventing ovarian cancer that could also reduce the need for invasive surgery.

Research Shows Potential for Breast Cancer Prevention in BRCA1-Driven Tumors

Research Shows Potential for Breast Cancer Prevention in BRCA1-Driven Tumors

By

The drug denosumab, which blocks a bone gene, may also prevent breast cancer caused by a BRCA1 mutation. This already approved drug could be available quickly, and would be the first drug for breast cancer prevention.

BRCA1/2 Testing Recommendations Vary Between Black and White Patients

BRCA1/2 Testing Recommendations Vary Between Black and White Patients

By

Disparities in BRCA1/2 testing in black and white women is attributable to differences in physician recommendations, according to a recent study.

Nipple-sparing Mastectomy Safe for Women With High Risk of Breast Cancer

Nipple-sparing Mastectomy Safe for Women With High Risk of Breast Cancer

By

Prophylactic nipple-sparing mastectomy is as effective at preventing breast cancer as more invasive surgeries, according to a multi-institution study.

<i>BRCA1</i> Mutation May Reduce Women's Fertility

BRCA1 Mutation May Reduce Women's Fertility

The BRCA1 mutation may speed the aging of a woman's ovaries,according to a recent report.

Genetic Testing for BRCA Gene Mutations Increasing Among Younger Women With Breast Cancer

By

Among women age 40 years or younger, rates of genetic testing for BRCA1 and BRCA2 mutations have increased, according to a recent study.

<i>BRCA</i> Mutation Testing Rates on the Increase in Young Women

BRCA Mutation Testing Rates on the Increase in Young Women

Among young women diagnosed with breast cancer, frequency of testing 95 percent in 2013

Additional Genes Linked With Ovarian Cancer Risk Identified

By

The researchers found that nearly one fifth of women with ovarian cancer carried mutations in genes that were associated with ovarian cancer risk beyond the BRCA1 and BRCA2 genes.

Black women have higher frequency of BRCA mutations than previously reported

By

Young black women with a breast cancer diagnosis at age 50 years or younger have a much higher BRCA mutation frequency than that previously reported among young white women with breast cancer.

Higher frequency of <i>BRCA</i> mutations observed in black women

Higher frequency of BRCA mutations observed in black women

In a study reviewing black women under 50 with invasive breast cancer, 12 percent had BRCA1 or BRCA2 mutations.

Research identifies factors in 'Angelina Jolie effect' on breast cancer screening

Research identifies factors in 'Angelina Jolie effect' on breast cancer screening

By

Research indicates that Angelina Jolie's announcement that she had tested positive for BRCA1 influenced some women's intentions to seek out similar genetic testing.

BRCA-targeting drug has benefit in prostate cancer

By

Trials results indicate that the pioneering drug olaparib, which targets inherited mutations, can be beneficial for men with prostate cancer.

Genetic testing should be accessible to all women with ovarian cancer

By

Women with ovarian cancer should be tested for BRCA1 and BRCA2 gene mutations, regardless of their family history.

Oophorectomy may decrease in breast cancer death in women with cancer and BRCA1 mutation

By

Oophorectomy is linked to a 62% reduction in breast cancer death for women diagnosed with breast cancer that carry a BRCA1 gene mutation.

Risk of ovarian cancer may differ by type of BRCA1 or BRCA2 mutation

By

Researchers have identified mutations that were associated with significantly different risks of breast and ovarian cancers, which may have implications for risk assessment and cancer prevention decision making among carriers of these mutations.

Previvorship: Managing Cancer Risk Decisions in Unaffected BRCA-positive Women

Previvorship: Managing Cancer Risk Decisions in Unaffected BRCA-positive Women

By

Four major themes characterize the experience of cancer risk management for women who are positive for BRCA genetic mutations.

Magnetic resonance spectroscopy (MRS) shows precancerous breast changes in women with BRCA gene mutation

By

MRS that incorporates monitoring of biochemical changes in tissue could improve the management of women at risk of breast cancer, according to a new study.

Correlated spectroscopy pinpoints changes in <i>BRCA1/2</i> carriers

Correlated spectroscopy pinpoints changes in BRCA1/2 carriers

Lipid and metabolite deregulation were seen in breast tissue of women carrying BRCA1/2 mutations.

Conventional therapies are less effective in prostate cancer with BRCA mutations

By

Prostate cancer patients with hereditary mutations in the BRCA genes do not respond as well to conventional treatment such as surgery and radiotherapy, and they have a lower survival rate than patients who do not have these genetic mutations.

BRCA-related tumors respond to olaparib

By

Olaparib, an experimental oral cancer drug, has shown an overall tumor response rate of 26% in advanced cancers associated with BRCA1 and BRCA2 mutations, according to recent research.

Telephone Support Intervention Beneficial for <i>BRCA</i> Carriers

Telephone Support Intervention Beneficial for BRCA Carriers

Reduction in distress, unmet information needs with telephone-based, peer-support program

Companion diagnostic test improves detection of BRCA mutations in patients with ovarian cancer

By

The Tumor BRACAnalysis CDx companion diagnostic test boosted the detection of cancer-causing BRCA1/2 mutations in women with ovarian cancer by over 40 percent.

Preoperative BRCA testing changes women's decisions about extent of surgery

By

A new study found that 72% of women with breast cancer who underwent BRCA testing before surgery and learned they were BRCA positive changed their surgical treatment plans.

Variation in BRCA2 gene linked to lung cancer, doubles a smoker's risk

By

New research confirms a vulnerability to lung cancer can be inherited and implicates the BRCA2 gene as harboring one of the involved genetic mutations.

pCR Not a surrogate for relapse-free survival in TNBC BRCA1/2 mutation carriers

pCR Not a surrogate for relapse-free survival in TNBC BRCA1/2 mutation carriers

By

In patients with triple-negative breast cancer (TNBC) who are BRCA1/2 mutation carriers, pathologic complete response (pCR) is not a surrogate for relapse-free survival, in contrast to those with non-BRCA mutations.

Large panel genetic testing in breast cancer produces more questions than answers

By

Although large genetic testing panels promise to uncover clues about patients' DNA, a team of researchers has found that those powerful tests tend to produce more questions than they answer.

Ovarian cancer risk reduced nonsurgical options for those with BRCA mutations

By

Breastfeeding, tubal ligation, and oral contraceptives may lower the risk of ovarian cancer for some women with BRCA gene mutations, according to a comprehensive analysis.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs